Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Exenatide

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

AstraZeneca · Phase 3 · Completed · Enrollment 119

NCT02635386

ArmPopulationDoseWeeksEstimandWeight change
Exenatide once weekly (EQW )Obesity or overweightn/r4n/r3.8% at week 24
Dapagliflozin (DAPA)Obesity or overweightn/r4n/r1.5% at week 24
EQW plus DAPAObesity or overweightn/r4n/r6.9% at week 24
Dapagliflozin plus Glucophage (MET ER)Obesity or overweightn/r4n/r1.7% at week 24
Phentermine /Topiramate (PHEN/ TPM) ERObesity or overweightn/r4n/r8.1% at week 24